Want to see TSE:APLI full AI Analyst Report?
Top Page
Appili Therapeutics Inc Class A
(APLI)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.01
▲(0.00% Upside)
Action:Reiterated
Date:09/25/26
The score is held down primarily by weak financial performance (deep losses, negative equity, and ongoing cash burn) that increases financing and dilution risk. Technicals add a secondary headwind as the stock trades below major moving averages with negative MACD. Valuation provides limited offset because the negative P/E reflects unprofitability and no dividend yield support is indicated.
Positive Factors
Reported Revenue Growth
The reported revenue growth rate indicates that the company has expanded its current revenue base materially. If supported by continued development progress and customer or partner activity, this growth can improve operating leverage and strengthen the commercial foundation over the next several quarters.
Negative Factors
Severely Stressed Balance Sheet
Negative equity and debt that materially exceeds the asset base indicate very limited financial flexibility. This structure can constrain investment in clinical programs, increase refinancing dependence, and raise the likelihood that future funding could dilute existing shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Reported Revenue Growth
The reported revenue growth rate indicates that the company has expanded its current revenue base materially. If supported by continued development progress and customer or partner activity, this growth can improve operating leverage and strengthen the commercial foundation over the next several quarters.
Read all positive factors
Appili Therapeutics Inc Class A (APLI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$661.83K
Dividend YieldN/A
Average Volume (3M)64.78K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth249.12%
EPS Growth-93.09%
CountryCA
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding132,366,120
10 Day Avg. Volume136,983
30 Day Avg. Volume64,782
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Appili Therapeutics Inc Class A Business Overview & Revenue Model
Company Description
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pi...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Appili’s ability to generate recurring product sales depends on successfully developing and commercializing drug candidates; specific, current commercial product revenue details are not available in t...
Appili Therapeutics Inc Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
7
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 378.81K | 244.18K | 100.44K | 827.41K | 334.18K | 1.39M |
| Gross Profit | 372.99K | 236.09K | 100.44K | 827.41K | 327.91K | 1.39M |
| EBITDA | -5.86M | -6.53M | 360.57K | -2.07M | -8.10M | -23.51M |
| Net Income | -4.68M | -4.24M | -2.62M | -3.78M | -9.24M | -25.12M |
Balance Sheet | ||||||
| Total Assets | 1.30M | 1.97M | 3.03M | 1.49M | 3.13M | 8.28M |
| Cash, Cash Equivalents and Short-Term Investments | 138.68K | 40.00K | 1.23M | 94.49K | 2.47M | 6.66M |
| Total Debt | 13.33M | 12.94M | 12.29M | 8.18M | 7.67M | 4.98M |
| Total Liabilities | 20.32M | 19.30M | 16.43M | 12.42M | 10.53M | 11.55M |
| Stockholders Equity | -19.02M | -17.33M | -13.40M | -10.92M | -7.40M | -3.27M |
Cash Flow | ||||||
| Free Cash Flow | -1.32M | -1.38M | 866.46K | -2.49M | -10.10M | -19.08M |
| Operating Cash Flow | -1.35M | -1.38M | 868.82K | -2.46M | -10.10M | -19.08M |
| Investing Cash Flow | 0.00 | 0.00 | -2.36K | -29.06K | -3.17K | 5.06M |
| Financing Cash Flow | 350.30K | 197.82K | 193.68K | 122.05K | 5.91M | 9.56M |
Appili Therapeutics Inc Class A Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
45.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APLI.
Appili Therapeutics Inc Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$577.68K | 1.45 | 34.52% | ― | ― | ― | |
47 Neutral | C$44.21M | -13.64 | 12.68% | ― | 45.72% | 35.82% | |
41 Neutral | C$661.83K | -0.14 | 27.40% | ― | 249.12% | -93.09% | |
41 Neutral | C$5.74M | -2.05 | 273.53% | ― | ― | ― | |
29 Underperform | C$2.04M | -0.91 | 69.89% | ― | ― | ― |
* Healthcare Sector Average
TSE:APLI
Appili Therapeutics Inc Class A
0.01
-0.02
-66.67%
TSE:KNE
Kane Biotech
0.03
-0.02
-37.50%
TSE:MIR
Medmira
0.06
-0.03
-30.00%
TSE:VXL
Vaxil Bio
0.15
-0.06
-27.50%
TSE:BIOV
BioVaxys Technology
0.07
-0.21
-75.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.